Oncology Adjuvants Market - Top Companies and Manufacturers

  • Report ID: 5860
  • Published Date: Mar 11, 2024
  • Report Format: PDF, PPT

Companies Dominating the Oncology Adjuvants Landscape

    • Sanofi S.A
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    •  Amgen Inc.
    • Bristol Myers Squibb
    • Eli Lilly and Company
    • Biogen AstraZeneca plc
    • Pfizer Inc.
    • Jiangsu Hengrui Pharmaceuticals Co., Ltd.
    • SL Pharmaceutical
    • Sanjiu Medical
    • Hisun Pharmaceuticals USA Inc.

Browse Key Market Insights with Data Illustration:

In the News

  • The benefit and feasibility of a novel approach to surgical treatment in NSCLC was demonstrated by the AEGEAN trial in June 2021. In patients with non-small cell lung cancer, combining neoadjuvant durvalumab with platinum-based chemotherapy, taken after by curative-intent surgery and adjuvant durvalumab progressed antitumor action and diminished repeat chance. In addition, perioperative durvalumab increased the rate of pathologic complete response by 12.9% when compared to placebo.
  • Merck known as MSD outside of the United States and Canada, announced that the U.S. Food and Drug Administration has approved KEYTRUDA, Merck’s anti-PD-1 therapy, as a single agent, for adjuvant treatment following surgical resection and platinum-based chemotherapy for adult patients with stage IB, II, or IIIA non-small cell lung cancer.

Author Credits:  Radhika Gupta, Shivam Bhutani

  • Report ID: 5860
  • Published Date: Mar 11, 2024
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

The growing prevalence of cancer and increasing number of cancer research intitutes are some of the major factors anticipated to drive the growth of the oncology adjuvant market.

The market is anticipated to attain a CAGR of ~5% over the forecast period, i.e., 2024-2036.

The major players in the market are of Amgen Inc., Bristol Myers Squibb, Eli Lilly and Company, Biogen AstraZeneca plc, Pfizer Inc., Jiangsu Hengrui Pharmaceuticals Co., Ltd., and others.

The cancer hospital segment is anticipated to garner the largest market size by the end of 2036 and display significant growth opportunities.

The market in North America is projected to hold the largest market share by the end of 2036 and provide more business opportunities in the future.
Inquiry Before Buying Request Free Sample

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying